Moderna withdraws FDA filing for flu/COVID combination vaccine, plans resubmission with efficacy data

Moderna has withdrawn its FDA application for its flu/COVID combination vaccine, mRNA-1083, initially slated for potential approval in late 2025 for adults aged 50 and older. The decision follows the FDA's request for Phase 3 efficacy data from Moderna's standalone flu vaccine, mRNA-1010, which is expected this summer. Moderna plans to resubmit the application later this year incorporating the requested efficacy data, potentially delaying approval until 2026.

Analysis

Moderna has voluntarily withdrawn its Biologics License Application (BLA) for its mRNA-1083 flu/COVID combination vaccine, which was initially submitted for adults aged 50 and older. This action was taken after the U.S. Food and Drug Administration (FDA) requested the inclusion of Phase 3 efficacy data from Moderna's standalone flu vaccine, mRNA-1010, prior to making an authorization decision. Consequently, the projected approval date for mRNA-1083 has been deferred from an anticipated November 2025 to 2026. Moderna intends to resubmit the application later this year, incorporating the mRNA-1010 efficacy data, with interim results from the 40,000-participant Phase 3 trial for mRNA-1010 expected in the summer. According to Moderna's President, Stephen Hoge, M.D., incorporating this data is scientifically sound, and interactions with the FDA remain "business as usual" and "productive." This development signifies a notable timeline adjustment for a key pipeline candidate, and while the per-ticker sentiment for MRNA (-0.2) indicates a slightly negative market perception, it suggests the market may view this as a manageable procedural delay contingent upon the strength of the upcoming flu vaccine efficacy data.

Key Decisions for Investors

• Investors should recalibrate launch timelines and associated revenue forecasts for the mRNA-1083 combination vaccine, pushing expectations from late 2025 to 2026.
• The forthcoming interim Phase 3 efficacy data for Moderna's standalone flu vaccine, mRNA-1010, expected this summer, represents a critical catalyst; its positive outcome is essential for the successful resubmission and approval of the combination vaccine.
• Despite Moderna's characterization of FDA interactions as productive, the withdrawal and resubmission process introduces an execution risk that warrants careful monitoring, even if current market sentiment appears relatively neutral regarding the delay.